Trial reportFrontiers in pharmacology2026
Effects of
Trial report in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with rheumatoid arthritis (RA) and concomitant fibromyalgia (FM) frequently experience severe, refractory pain, elevated disease activity scores, and substantial psychological distress. Conventional treatments frequently fail to adequately address this complex pain syndrome, and evidence-based traditional Chinese medicine (TCM) interventions for this specific comorbidity remain limited. This pilot study aimed to assess the feasibility of a definitive trial and preliminarily evaluate the efficacy and safety of Methods: In this randomized, double-blind, placebo-controlled pilot trial, 30 patients diagnosed with both RA and FM were randomly assigned (1:1) to receive either SHG (n = 15) or matching placebo (n = 15) twice daily for 4 weeks, followed by an 8-week follow-up. The primary outcome was the change in pain intensity measured by visual analog scale (VAS). Secondary outcomes included patient and physician global assessments (PGA, PhGA), tender and swollen joint counts (TJC, SJC), FM-specific measures (WPI, SSS, FIQ), and assessments of fatigue, sleep quality, anxiety, and depression. Safety was monitored through adverse event recording and laboratory tests. Results: Twenty-six patients completed the trial (placebo completers n = 11 vs. SHG n = 15). Linear mixed-effects models showed significant group × time interactions for VAS ( Conclusion: This pilot study provides preliminary evidence that SHG may offer short-term benefits in reducing pain and improving physical function, sleep, fatigue, and psychological wellbeing in patients with RA and comorbid FM, with a safety profile comparable to placebo. While these preliminary findings support the potential of SHG as a therapeutic option, they require confirmation in larger, multicenter trials with extended follow-up to establish definitive efficacy and explore underlying mechanisms. Clinical Rehabilitation Impact: SHG may represent a promising complementary therapy for relieving chronic pain and improving overall health in patients with RA complicated by FM. Larger, multicenter trials with extended follow-up are warranted to confirm these findings, explore underlying mechanisms, and define its role in integrative management strategies. Clinical Trial Registration: Chinese Clinical Trial Registry (ChiCTR), https://www.chictr.org.cn/showproj.html?proj=221912, Identifier ChiCTR2400081980.18 March 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.